SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma

被引:10
|
作者
Venugopalan, Abhilash [1 ]
Lynberg, Matthew [1 ]
Cultraro, Constance M. [1 ]
Nguyen, Khoa Dang P. [1 ]
Zhang, Xu [1 ]
Waris, Maryam [1 ]
Dayal, Noelle [1 ]
Abebe, Asebot [1 ]
Maity, Tapan K. [1 ]
Guha, Udayan [1 ,2 ]
机构
[1] NCI, Thorac & GI Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] Bristol Myers Squibb, Lawrenceville, NJ 08648 USA
关键词
D O I
10.1038/s41388-021-01764-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain constitutively activate EGFR resulting in lung tumorigenesis. Activated EGFR modulates downstream signaling by altering phosphorylation-driven interactions that promote growth and survival. Secretory carrier membrane proteins (SCAMPs) are a family of transmembrane proteins that regulate recycling of receptor proteins, including EGFR. The potential role of SCAMPs in mutant EGFR function and tumorigenesis has not been elucidated. Using quantitative mass-spectrometry-based phosphoproteomics, we identified SCAMP3 as a target of mutant EGFRs in lung adenocarcinoma and sought to further investigate the role of SCAMP3 in the regulation of lung tumorigenesis. Here we show that activated EGFR, either directly or indirectly phosphorylates SCAMP3 at Y86 and this phosphorylation increases the interaction of SCAMP3 with both wild-type and mutant EGFRs. SCAMP3 knockdown increases lung adenocarcinoma cell survival and increases xenograft tumor growth in vivo, demonstrating a tumor suppressor role of SCAMP3 in lung tumorigenesis. The tumor suppressor function is a result of SCAMP3 promoting EGFR degradation and attenuating MAP kinase signaling pathways. SCAMP3 knockdown also increases multinucleated cells in culture, suggesting that SCAMP3 is required for efficient cytokinesis. The enhanced growth, increased colony formation, reduced EGFR degradation and multinucleation phenotype of SCAMP3-depleted cells were reversed by re-expression of wild-type SCAMP3, but not SCAMP3 Y86F, suggesting that Y86 phosphorylation is critical for SCAMP3 function. Taken together, the results of this study demonstrate that SCAMP3 functions as a novel tumor suppressor in lung cancer by modulating EGFR signaling and cytokinesis that is partly Y86 phosphorylation-dependent.
引用
收藏
页码:3331 / 3346
页数:16
相关论文
共 50 条
  • [21] Management of stage IA EGFR-mutant adenocarcinoma of the lung
    Pirker, Robert
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S3260 - S3262
  • [22] Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in EGFR-Mutant Lung Adenocarcinoma
    Li, Teng
    Pang, Xiaocong
    Wang, Junyun
    Wang, Shouzheng
    Guo, Yiying
    He, Ning
    Xing, Puyuan
    Li, Junling
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [23] Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with EGFR-mutant lung cancer
    Stockhammer, Paul
    Grant, Michael J.
    Wurtz, Anna
    Foggetti, Giorgia
    Exposito, Francisco
    Gu, Jianlei
    Chung, Sangyun
    Li, Fangyong
    Walther, Zenta
    Gettinger, Scott N.
    Politi, Katerina A.
    Goldberg, Sarah B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Acquired ALK Rearrangement in EGFR-Mutant Lung Adenocarcinoma Treated with EGFR TKIs
    Wang, Q.
    Chen, R.
    Kang, J.
    Chen, H.
    Wang, B.
    Wang, Z.
    Zhou, Q.
    Wu, Y.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S569 - S570
  • [25] Role of tyrosine phosphorylation of β-catenin in EGFR-mutant lung cancer
    Fujii, Masanori
    Nakayama, Sohei
    Shimizu, Kohei
    Takei, Hisashi
    Ando, Mariko
    Heo, Eunyoung
    Kobayashi, Ikei
    Pan, Gilbert
    Inuzuka, Hiroyuki
    Kobayashi, Susumu
    CANCER RESEARCH, 2018, 78 (13)
  • [26] Biased signaling by mutant EGFR underlies dependence on PKCa in lung adenocarcinoma
    Sadeghi, Mojtaba
    Salama, Mohamed F.
    Chiappone, Sam B.
    Huang, Amy
    Resnick, Andrew E.
    Kandpal, Manoj
    Clarke, Christopher J.
    Haley, John D.
    Davuluri, Ramana V.
    Hannun, Yusuf A.
    CELL REPORTS, 2024, 43 (12):
  • [27] MOLECULAR HETEROGENEITY AND RESPONSE TO GEFITINIB OF EGFR MUTANT ADVANCED LUNG ADENOCARCINOMA
    Bria, E.
    Pilotto, S.
    Amato, E.
    Fassan, M.
    Novello, S.
    Vavala, T.
    Righi, L.
    Sperduti, I.
    Scarpa, A.
    Tortora, G.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S38 - S39
  • [28] Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
    Shen, C-I.
    Chiu, C-H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma
    Zhou, Wensheng
    Liu, Zhichao
    Wang, Yanan
    Zhang, Yanwei
    Qian, Fangfei
    Lu, Jun
    Wang, Huimin
    Gu, Ping
    Hu, Minjuan
    Chen, Ya
    Yang, Zhengyu
    Zhao, Ruiying
    Lou, Yuqing
    Han, Baohui
    Zhang, Wei
    CANCER MEDICINE, 2022, 11 (05): : 1299 - 1309
  • [30] Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages
    Wang, Don-Hong
    Lee, Hyun-Sung
    Yoon, David
    Berry, Gerald
    Wheeler, Thomas M.
    Sugarbaker, David J.
    Kheradmand, Farrah
    Engleman, Edgar
    Burt, Bryan M.
    CLINICAL CANCER RESEARCH, 2017, 23 (03) : 778 - 788